+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nanomedicine Market Analysis By Products, By Drug Delivery System, By Application And Segment Forecasts to 2028

  • ID: 5360598
  • Report
  • July 2020
  • Region: Global
  • 244 pages
  • Reports and Data

FEATURED COMPANIES

  • AMAG Pharmaceuticals
  • Bio-Gate AG
  • Celgene Corporation
  • Johnson & Johnson.
Increasing prevalence of cardiovascular diseases, diabetes, and other infectious diseases is expected to create demand for Nanomedicines, which is a key factor driving market revenue growth.

Market Size - USD 167.53 Billion in 2020, Market Growth - CAGR of 12.6%, Market Trends - Rising prevalence of various chronic diseases globally, and increasing investments R&D of advanced and novel medicines by major players.

The global Nanomedicine market size is expected to reach USD 432.30 Billion in 2028, and register a CAGR of 12.6% during the forecast period. Increasing number of cases of cardiovascular diseases (CVD), especially in developed countries is expected to drive demand and need for advanced medicines to treat CVD. This is a major factor expected to drive growth of the global Nanomedicine market. According to statistics, cardiovascular diseases is America’s leading health issue and the major cause of deaths in the region. Around 84 million people in America have been estimated to suffer from some form of cardiovascular disease, thereby causing about 2,200 deaths a day.

Nanomedicine is expected to be adopted significantly for treatment of various types of cancer due to drawbacks associated with cancer therapies such as chemotherapy. This is another major factor boosting market growth.

Some Key Findings From the Report:
  • Among the application segments, the oncology segment accounted for the largest revenue share of 28.5% in 2020.
  • The Asia Pacific market size was USD 46.15 Billion in 2020, due to increasing adoption of Nanomedicine for treatment of cancer and cardiovascular diseases in countries in the region.
  • Key players profiled in the report include Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
  • In 2018, Ardena, a contract development and manufacturing organisation (CDMO), made a number of investments in expanding its nanomedicine technology portfolio. It would thus be offering services like development and GMP manufacturing of crystalline nanosuspensions, liposomes, iron oxide nanoparticles, and polymeric nanoparticles.
For the purpose of this report, the global Nanomedicine market is segmented on the basis of product, drug delivery system, application, and region:

Product Outlook (Revenue, USD Billion; 2018 - 2028)
  • Therapeutics
  • Regenerative Medicine
  • In-vitro diagnostics
  • In-vivo diagnostic
  • Vaccines
Drug Delivery System Outlook (Revenue, USD Billion; 2018 - 2028)
  • Nanobots
  • Nanoghosts
  • Nanoclusters
  • Nanobubbles
  • Exosomes
  • Injectable Nanoparticle Generator
  • Dendrimers
  • Liposomes
  • Carbon nanotube
  • Graphene
  • Others
Application Outlook (Revenue, USD Billion; 2018 - 2028)
  • Oncology
  • Infectious diseases
  • Cardiology
  • Orthopedics
  • Others
Region Outlook (Revenue, USD Billion; 2018 - 2028)
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Benelux
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Rest of Latin America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa
Reasons to Buy the Report
  • A robust analysis and estimation of the Nanomedicine Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
  • A holistic competitive landscape of the all the major players in the Nanomedicine Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
  • Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
  • Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
  • Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AMAG Pharmaceuticals
  • Bio-Gate AG
  • Celgene Corporation
  • Johnson & Johnson.
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary
2.1. Summary Snapshot, 2018-2026

Chapter 3. Indicative Metrics
3.1. Macro Indicators
3.1.1. Increasing incidence of cancer
3.1.2. Rising prevalence of cardiovascular diseases

Chapter 4. Nanomedicine Market Segmentation & Impact Analysis
4.1. Nanomedicine Segmentation Analysis
4.2. Regulatory Framework
4.3. Technological Insights
4.4. Nanomedicine Market Impact Analysis
4.4.1. Market driver analysis
4.4.1.1. Increasing level of government participation in R&D funding
4.4.1.2. Rising adoption of nanomedicine in drug delivery technology
4.4.2. Market restraint analysis
4.5. Key opportunities prioritized
4.6. Nanomedicine Competitive scenario, 2017

Chapter 5. Nanomedicine Market Product Insights & Trends
5.1. Product Dynamics & Market Share, 2018 & 2026
5.2. Therapeutics
5.2.1. Market estimates and forecast, 2016-2026 (USD Million)
5.2.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
5.3. Regenerative Medicine
5.3.1. Market estimates and forecast, 2016-2026 (USD Million)
5.3.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
5.4. In-vitro diagnostics
5.4.1. Market estimates and forecast, 2016-2026 (USD Million)
5.4.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
5.5. In-vivo diagnostic
5.5.1. Market estimates and forecast, 2016-2026 (USD Million)
5.5.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
5.6. Vaccines
5.6.1. Market estimates and forecast, 2016-2026 (USD Million)
5.6.2. Market estimates and forecast, by region, 2016-2026 (USD Million)

Chapter 6. Nanomedicine Market Nano-technology Based Drugs Insights & Trends
6.1. Nano-technology Based Drugs Dynamics & Market Share, 2018 & 2026
6.2. Paclitaxel
6.2.1. Market estimates and forecast, (USD Million)
6.2.2. Market estimates and forecast, by region, 2017–2026 2016-2026 (USD Million)
6.3. Daunorubicin
6.3.1. Market estimates and forecast, 2016-2026 (USD Million)
6.3.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
6.4. Cytarabine
6.4.1. Market estimates and forecast, 2016-2026 (USD Million)
6.4.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
6.5. Doxorubicin
6.5.1. Market estimates and forecast, 2016-2026 (USD Million)
6.5.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
6.6. Vincristine
6.6.1. Market estimates and forecast, 2016-2026 (USD Million)
6.6.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
6.7. Mifamurtide MTP-PE
6.7.1. Market estimates and forecast, 2016-2026 (USD Million)
6.7.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
6.8. L-asparaginase
6.8.1. Market estimates and forecast, 2016-2026 (USD Million)
6.8.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
6.9. Irinotecan
6.9.1. Market estimates and forecast, 2016-2026 (USD Million)
6.9.2. Market estimates and forecast, by region, 2016-2026 (USD Million)

Chapter 7. Nanomedicine Market Drug Delivery System Insights & Trends
7.1. Drug Delivery System Dynamics & Market Share, 2018 & 2026
7.2. Nanobots
7.2.1. Market estimates and forecast, (USD Million)
7.2.2. Market estimates and forecast, by region, 2017–2026 2016-2026 (USD Million)
7.3. Nanoghosts
7.3.1. Market estimates and forecast, 2016-2026 (USD Million)
7.3.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.4. Nanoclusters
7.4.1. Market estimates and forecast, 2016-2026 (USD Million)
7.4.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.5. Nanobubbles
7.5.1. Market estimates and forecast, 2016-2026 (USD Million)
7.5.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.6. Exosomes
7.6.1. Market estimates and forecast, 2016-2026 (USD Million)
7.6.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.7. Injectable Nanoparticle Generator
7.7.1. Market estimates and forecast, 2016-2026 (USD Million)
7.7.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.8. Dendrimers
7.8.1. Market estimates and forecast, 2016-2026 (USD Million)
7.8.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.9. Liposomes
7.9.1. Market estimates and forecast, 2016-2026 (USD Million)
7.9.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.10. Carbon Nanotube
7.10.1. Market estimates and forecast, 2016-2026 (USD Million)
7.10.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.11. Graphene
7.11.1. Market estimates and forecast, 2016-2026 (USD Million)
7.11.2. Market estimates and forecast, by region, 2016-2026 (USD Million)
7.12. Others
7.12.1. Market estimates and forecast, 2016-2026 (USD Million)
7.12.2. Market estimates and forecast, by region, 2016-2026 (USD Million)

Chapter 8. Nanomedicine Market Application Insights & Trends
8.1. Application Dynamics & Market Share, 2018 & 2026
8.2. Oncology
8.2.1. Market estimates and forecast, 2017–2026, (USD Million)
8.2.2. Market estimates and forecast, by region, 2017–2026, (USD Million)
8.3. Infectious Diseases
8.3.1. Market estimates and forecast, 2017–2026, (USD Million)
8.3.2. Market estimates and forecast, by region, 2017–2026, (USD Million)
8.4. Cardiology
8.4.1. Market estimates and forecast, 2017–2026, (USD Million)
8.4.2. Market estimates and forecast, by region, 2017–2026, (USD Million)
8.5. Orthopedics
8.5.1. Market estimates and forecast, 2017–2026, (USD Million)
8.5.2. Market estimates and forecast, by region, 2017–2026, (USD Million)
8.6. Others
8.6.1. Market estimates and forecast, 2017–2026, (USD Million)
8.6.2. Market estimates and forecast, by region, 2017–2026, (USD Million)

Chapter 9. Nanomedicine Regional Outlook
9.1. Nanomedicine Market share by region, 2018 & 2026
9.2. North America
9.2.1. North America Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.2.2. North America Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.2.3. North America Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.2.4. North America Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.2.5. North America Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.2.6. U.S.
9.2.6.1. U.S. Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.2.6.2. U.S. Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.2.6.3. U.S. Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.2.6.4. U.S. Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.2.6.5. U.S. Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.3. Europe
9.3.1. Europe Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.3.2. Europe Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.3.3. Europe Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.3.4. Europe Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.3.5. Europe Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.3.6. Germany
9.3.6.1. Germany Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.3.6.2. Germany Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.3.6.3. Germany Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.3.6.4. Germany Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.3.6.5. Germany Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.3.7. UK
9.3.7.1. UK Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.3.7.2. UK Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.3.7.3. UK Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.3.7.4. UK Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.3.7.5. UK Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.4.2. Asia Pacific Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.4.3. Asia Pacific Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.4.4. Asia Pacific Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.4.5. Asia Pacific Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.4.6. China
9.4.6.1. China Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.4.6.2. China Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.4.6.3. China Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.4.6.4. China Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.4.6.5. China Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.4.7. India
9.4.7.1. India Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.4.7.2. India Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.4.7.3. India Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.4.7.4. India Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.4.7.5. India Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.5. Latin America
9.5.1. Latin America Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.5.2. Latin America Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.5.3. Latin America Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.5.4. Latin America Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.5.5. Latin America Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.5.6. Brazil
9.5.6.1. Brazil Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.5.6.2. Brazil Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.5.6.3. Brazil Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.5.6.4. Brazil Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.5.6.5. Brazil Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)
9.6. MEA
9.6.1. MEA Nanomedicine Market estimates and forecast, 2017–2026, (USD Million)
9.6.2. MEA Nanomedicine Market estimates and forecast by Product, 2016-2026, (USD Million)
9.6.3. MEA Nanomedicine Market estimates and forecast by Nano-technology based Drugs, 2016-2026, (USD Million)
9.6.4. MEA Nanomedicine Market estimates and forecast by Drug Delivery System, 2016-2026, (USD Million)
9.6.5. MEA Nanomedicine Market estimates and forecast by Application, 2016-2026, (USD Million)

Chapter 10. Competitive Landscape
10.1. Market Revenue Share by Manufacturers
10.2. Manufacturing Cost Breakdown Analysis
10.3. Mergers & Acquisitions
10.4. Market positioning
10.5. Strategy Benchmarking
10.6. Vendor Landscape

Chapter 11. Company Profiles
11.1. Arrowhead Pharmaceuticals, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Insights
11.1.4. Strategic Initiatives
11.2. Brigham and Women's Hospital (BWH)
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Insights
11.2.4. Strategic Initiatives
11.3. Nanospectra Biosciences, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Insights
11.3.4. Strategic Initiatives
11.4. ABLYNX
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Insights
11.4.4. Strategic Initiatives
11.5. AMAG Pharmaceuticals
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Insights
11.5.4. Strategic Initiatives
11.6. Bio-Gate AG
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Insights
11.6.4. Strategic Initiatives
11.7. Celgene Corporation
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Insights
11.7.4. Strategic Initiatives
11.8. Johnson & Johnson Services, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Insights
11.8.4. Strategic Initiatives
11.9. Pfizer, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Insights
11.9.4. Strategic Initiatives 
11.10. Abbott
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Insights
11.10.4. Strategic Initiatives
11.11. Leadiant Biosciences, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Insights
11.11.4. Strategic Initiatives
Note: Product cover images may vary from those shown
  • Arrowhead Pharmaceuticals Inc.
  • AMAG Pharmaceuticals
  • Bio-Gate AG
  • Celgene Corporation
  • Johnson & Johnson.
Note: Product cover images may vary from those shown
Adroll
adroll